Europe PMC

Psoriasis is a systemic immune‑mediated skin disease, typically considered to be incurable. Identification of meaningful biomarkers has been a notable challenge in psoriasis prevention and management. The present study aimed to determine the signature genes driving psoriasis and their underlying mechanism. Microarray datasets of psoriasis were obtained from the Gene Expression Omnibus database, and the differentially expressed genes (DEGs) were identified using the 'limma' R package. Gene Set En

Atherosclerosis is now considered to reflect systemic inflammation involving the elevation of multiple proinflammatory cytokines, sharing common underlying pathophysiological mechanisms with psoriasis. There has been increasing interest in whether anti-inflammatory treatment of psoriasis can prevent or halt the progression of atherosclerosis. Here, we conducted a cross-sectional observational clinical study in psoriasis patients with at least one traditional cardiovascular risk factor, such as d

Psoriasis is a prevalent chronic inflammatory skin disease that significantly reduces patients' quality of life. Current treatments have limited efficacy and severe side effects, necessitating the development of new drugs. Notopterygii rhizoma et radix (Qiang Huo, QH), a Traditional Chinese Medicine (TCM) herb commonly studied for psoriasis patterns and treatment, requires further clarifications of its pharmacological mechanism. This study first verified the therapeutic effects of QH on Imiquimo

No abstract supplied.Weiterlesen

Interleukin-23 (IL-23) plays a pivotal role in the intricate interplay between the skin, gut, and joints, contributing significantly to the pathogenesis of various inflammatory diseases including psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD) and Behcet's disease. In recent years, several IL-23 inhibitors have been granted approval for the treatment of psoriasis, PsA and IBD. As up to one-third of patients diagnosed with psoriasis may go on to develop PsA and given the st

Objectives The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used to assess axial disease activity in psoriatic arthritis (PsA). However, 5 of its 6 questions reflect general disease activity rather than axial-specific symptoms. We aimed to evaluate the performance of BASDAI and its back pain subscore in assessing axial disease in PsA.Methods Patients with BASDAI scores were identified from a longitudinal PsA cohort initiated in 1978. Axial disease was defined radiographi

Psoriasis is a chronic inflammatory skin disease associated with an increased risk of developing cardiovascular disease. Various environmental factors contribute to disease development in genetically susceptible individuals. Although infections have been associated with disease initiation and recurrence, the consequences of early exposure to infections, many years before disease manifestation, is unexplored. To investigate the effect of exposure to infections during formative years on the incide

Rheumatoid arthritis (RA) is the most common inflammatory joint disease worldwide. T-cell inhibitors, tumor necrosis factor inhibitors, interleukin inhibitors (ILIs), Janus kinase inhibitors, and B-cell depletion therapy are indicated as second-line therapy and are prescribed for other inflammatory autoimmune conditions (ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn disease, ulcerative colitis) co-occurring in an estimated 7% to 20% of patients with RA but are routinely excluded

Chronic inflammatory diseases such as psoriasis (PsO) and psoriatic arthritis (PsA) are associated with a high disease burden and significant healthcare needs. Given limited specialist resources, the use of medical health apps is increasingly coming into focus as a means of supporting patients in self-management and closing gaps in care. This review highlights digital health applications available in Germany for PsO and PsA. Their functions, objectives, and potential benefits in the context of c

Psoriasis is a chronic inflammatory skin disorder affecting 2-3% of the global population. It is increasingly recognized for its systemic comorbidities, especially cardiovascular diseases (CVDs). Notably, severe psoriasis independently increases cardiovascular disease (CVD) risk. This elevation occurs beyond conventional risk factors, such as hypertension and diabetes. It suggests that shared inflammatory pathways underlie the association between severe psoriasis and atherosclerotic conditions,

Background Several traditional observational studies have reported an association between uveitis and psoriatic arthritis (PsA). However, the causal relationship between them remains unclear. Objective To investigate whether genetically predicted uveitis is related to the risk of PsA, and vice versa. Methods A two-sample bidirectional Mendelian randomisation (MR) design was employed, conducting a meta-analysis on data sourced from three distinct origins, followed by sensitivity analyses to ensur

Numerous case reports have documented the coexistence of psoriasis and pemphigus. We present the case of a man with a history of psoriasis who subsequently developed pemphigus. We review relevant case reports published over the past decade. Available evidence suggests that pemphigus may develop in patients with a history of psoriasis.Weiterlesen

Psoriasis is a chronic skin disease characterized by keratinocyte hyperproliferation, epidermal hyperplasia, and immune cell infiltration involving both innate and adaptive immune systems. Bromodomain-containing protein 4 (BRD4), part of the Bromodomain and Extra-Terminal (BET) family, is implicated in various inflammatory and hyperproliferative disorders, though its role in psoriasis is unclear. This study investigates BRD4's role in psoriasis pathogenesis using BRD4-specific small interfering

Introduction Psoriasis (PsO) in the genital and scalp areas is associated with increased patient burden and impact on quality of life. Effective treatments for PsO in these high-impact areas are essential, though patients are frequently excluded from both biologic clinical trials and treatment because of their often low overall affected body surface area (BSA) despite the disproportionate impact of PsO on their quality of life. Recent guidance also considers these patients as candidates for adva

Introduction Mental health status potentially influences treatment responses. The effect of probable anxiety and/or depressive disorder (pADD) on tofacitinib efficacy, patient-reported outcomes (PROs), and safety in psoriatic arthritis (PsA) was assessed.Methods This was a post hoc analysis of two phase 3 trials in patients with PsA receiving tofacitinib, adalimumab, or placebo, and an open-label extension study. Outcomes were stratified by presence/absence of baseline pADD (Short Form-36 Health

Objective To investigate the association between peripheral disease activity and pre-eclampsia, gestational hypertension, preterm birth and fetal growth in women with psoriatic arthritis (PsA).Methods Data from a Norwegian nationwide register (RevNatus) were linked with data from the Medical Birth Registry of Norway (MBRN). Cases were singleton births in women with PsA with available disease activity assessment (n=109) included in RevNatus 2010 to 2019. Singleton births registered in MBRN during

Online health information (OHI) in dermatology often exceeds the recommended sixth-grade reading level, hindering patient comprehension. This study aimed to assess the utility of three artificial intelligence large language models (LLMs) - ChatGPT-3.5, ChatGPT-4, and Google Gemini - in enhancing the readability of OHI on generalized pustular psoriasis (GPP) while preserving the reliability and quality of the source material. Texts from the top 20 search results for GPP were reworded by LLMs to a

Introduction Cardiovascular disease is a leading co-morbidity in psoriasis patients. The cutaneous benefits of biologic therapies for severe plaque psoriasis are well-established, but the impact of biologics on major adverse cardiovascular events (MACE) in psoriatic patients requires further elucidation. This study aimed to investigate the impact of biologic therapies on the risk of MACE in patients with chronic plaque psoriasis.Methods We conducted a systematic review and meta-analysis on 10 Ma

Mitochondrial structural and functional changes accompany psoriasis, yet the mitochondrial response to psoriatic inflammation in keratinocytes and fibroblasts remains unexplored. In this study, we investigated the effect of psoriasis-like inflammation (PLI) induced by a cytokine cocktail (interleukin (IL)-17A, IL-22 and tumour necrosis factor (TNF)-α) on mitochondrial network morphology and function in cultured keratinocytes (HaCaT) and fibroblasts (BJ-5ta). In both cell types, PLI triggered the

Background Psoriasis is a chronic inflammatory skin disease often associated with obesity and metabolic dysfunction, which may worsen disease severity. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have shown metabolic and anti-inflammatory effects, but their impact on psoriasis in non-diabetic patients with obesity remains unclear.Objective To evaluate the effects of a six-month semaglutide treatment on psoriasis severity and clinical, metabolic, inflammatory, and psyc

Purpose To seek recommendations from a panel of experts in psoriatic arthritis (PsA) on the current management challenges, local practices, and role of interleukin (IL)-17 inhibitors in the United Arab Emirates (UAE) using evidence from phase III trials as background.Methods Nine rheumatologists who treat PsA in the UAE completed a structured survey and attended a meeting to discuss topics/issues identified in the survey. A literature search was performed to identify phase III randomized trials

Psoriasis (Pso) is a chronic inflammatory skin disease driven by T helper 17 (TH17) cells, with several clinical subtypes. While self-reactive immune responses have been observed, the role of autoantigens in Pso remains unclear. Using immunopeptidomics, we identified serpin family B member 3 (SERPINB3) and SERPINB4 as candidate autoantigens in Pso skin. In a mouse model, the SERPINB3 ortholog Serpinb3b enhanced inflammation, promoted tissue-resident memory T cells, and skewed immunity toward a T

Objective The concept of severity in psoriatic arthritis (PsA) remains inconsistently defined, often conflated with disease activity. This scoping review aimed to explore how severity has been defined in the PsA literature and to identify criteria used to characterize severe disease.Methods A scoping review was conducted in April 2025 following PRISMA-ScR guidelines. PubMed was searched for English-language articles from the last 25 years, alongside abstracts from major rheumatology conferences.

Objectives Several studies have reported weight gain with tumor necrosis factor inhibitors (TNFi) in psoriatic disease. However, such analyses have not accounted for the natural propensity for weight gain over time. We aimed to investigate whether therapy with TNFi in psoriatic arthritis (PsA) patients is associated with a change in the rate of weight gain post-treatment initiation.Methods We included patients with at least two weight measurements prior to, and after commencing TNFi and used cha

Background: Psoriasis is a systemic inflammatory disease associated with metabolic dysregulation. Understanding these metabolic changes may reveal biomarkers to elucidate disease mechanisms and predict comorbidities. While previous studies have identified psoriasis-associated metabolites, findings are often limited by sample sizes and lack validation. Objectives: We aimed to identify circulating metabolites associated with psoriasis, including cutaneous activity, severity, and psoriatic arthr